IL1A and COVID-19: COVID‐19 patients with neurological involvement exhibit significantly higher markers of systemic inflammation compared to those without neurological injury.[159] Moreover, research indicates that elevated levels of systemic cytokines such as IL‐6, IL‐8, and IL‐1 are associated with subsequent neuro‐axonal impairment in COVID‐19 individuals.[160] Therefore, it can be inferred that such a potent peripheral or systemic cytokine storm inevitably leads to adverse effects on the neurological system, resulting in neuroinflammation.